secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001171843-25-003044
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience Q1 net loss $50.3M includes $48M goodwill impairment; guides Q2 revenue $18-20M
--------------------------------------------------------------------------------

- Revenue $21.8M vs $24.5M YoY (-11%); net loss $(50.3)M vs $(4.7)M, including $48.0M goodwill impairment.
- Gross margin 56.0% vs 60.3% YoY; Adjusted EBITDA $0.8M vs $1.6M YoY.
- Q2 2025 guidance: revenue $18M-$20M, gross margin 55%-57%.
- CEO cites NIH funding uncertainty, tariff impact on China sales; cost savings ~$1M/qtr starting Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184325003044/0001171843-25-003044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184325003044/f8k_051225.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-003044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer